Effects of AT1-receptor blockade on progression of left ventricular dysfunction in dogs with heart failure

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 276, Issue 4 45-4, 1999, Pages

  Tanimura, Mitsuhiro ^a   Sharov, Victor G ^a   Shimoyama, Hisashi ^a   Mishima, Takayuki ^a   Levine, T Barry ^b   Goldstein, Sidney ^a   Sabbah, Hani N ^a,c  

^a HENRY FORD HEART AND VASCULAR INSTITUTE   (United States)

^b Botsford Hospital   (United States)

^c HENRY FORD HOSPITAL   (United States)

Author keywords

Angiotensin II receptor antagonists; Animal models; Congestive heart failure; Ventricular function; Ventricular remodeling

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; VALSARTAN; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR; DRUG DERIVATIVE; TETRAZOLE DERIVATIVE; VALINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOG; DRUG EFFECT; DRUG SCREENING; HEART AFTERLOAD; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; MICROEMBOLISM; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; ANIMAL; DISEASE COURSE; DOSE RESPONSE; DRUG ANTAGONISM; FORWARD HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; CARDIAC OUTPUT, LOW; DISEASE PROGRESSION; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN; TETRAZOLES; VALINE; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 0033113523     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.1999.276.4.h1385     Document Type: Article

References (43)

1. Asano, K., D. L. Dutcher, D. Port, W. A. Minobe, K. D. Tremmel, R. L. Roden, T. J. Bohlmeyer, E. W. Busch, M. J. Jenkin, W. T. Abraham, M. V. Raynolds, L. S. Zisman, M. B. Perryman, and M. R. Bristow. Selective downregulation of the angiotensin-II AT1-receptor subtype in failing human ventricular myocardium. Circulation 95: 1193-1200, 1997.
2. Azizi, M., G. Chatellier, T. T. Guyene, D. Murieta-Geoffroy, and J. Menard. Additive effects of combined angiotensin converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium depleted normotensives. Circulation 92: 825-834, 1995.
3. Balcells, E., Q. C. Meng, W. H. Johnson, Jr., S. Oparil, and L. J. Dell'Italia. Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am. J. Physiol. 273 (Heart Circ. Physiol. 42): H1769-H1774, 1997.
4. Carretero, O. A., and A. G. Scicli. The kallikrein-kinin system as a regulator of cardiovascular and renal function. In: Hypertension: Physiology, Diagnosis and Management, edited by J. H. Laragh and B. M. Brenner. New York: Raven, 1990, p. 983-999.
5. Chang, R. S. L., and V. J. Lotti. Angiotensin receptor subtypes in rat, rabbit and monkey tissues: relative distribution and species dependency. Life Sci. 49: 1485-1490, 1991.
6. Criscione, L., M. de Gasparo, P. Buhlmeyer, S. Whitebread, H. R. Ramjoue, and J. Wood. Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II ATI receptor subtype. Br. J. Pharmacol. 110: 761-771, 1993.
7. Crozier, I., H. Ikram, N. Awan, J. Cleland, N. Stephen, K. Dickstein, M. Frey, J. Young, G. Klinger, L. Makris, and E. Ricinska. Losartan in heart failure: hemodynamic effects and tolerability. Lasartan Hemodynamic Study Group. Circulation 91: 691-697, 1995.
8. Dell'Italia, L. J., Q. C. Meng, E. Balcells, I. M. Straeter-Knowich, G. Hankes, R. Dillon, R. E. Cartee, R. Orr, S. P. Bishop, S. Oparil, and T. Elton. Increased ACE and chymase-like activity in cardiac tissue of dogs with chronic mitral regurgitation. Am. J. Physiol. 269 (Heart Circ. Physiol. 38): H2065-H2073, 1995.
9. Dickstein, K., P. Chang, R. Willenheimer, S. Haunso, J. Remes, C. Hall, and J. Kjekshus. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe heart failure. J. Am. Coll. Cardiol. 26: 438-445, 1995.
10. Dodge, H. T., H. Sandler, W. A. Baxley, and R. R. Hawley. Usefulness and limitations of radiographic methods for determining left ventricular volume. Am. J. Cardiol. 18: 10-24, 1996.
11. Garg, R., and S. Yusuf. Overview of randomized trials of angiotensin converting enzyme inhibitors on mortality and morbidity in patients with heart failure. The Collaborative Group on ACE Inhibitor Trials. JAMA 273: 1450-1456, 1995.
12. Gavras H., and I. Gavras. Cardioprotective potential of angiotensin converting enzyme inhibitors. J. Hypertens. 9: 385-392, 1991.
13. Gavras, I. Bradykinin-mediated effects of ACE inhibition. Kidney Int. 42: 1020-1029, 1992.
14. Goldstein, S., V. G. Sharov, J. M. Cook, and H. N. Sabbah. Ventricular remodeling: insights from pharmacologic interventions with angiotensin-converting enzyme inhibitors. Mol. Cell. Biochem. 147: 51-55, 1995.
15. Haywood, G. A., L. Gullestad, T. Katsuya, H. G. Hutchinson, R. E. Pratt, M. Horiuchi, and M. B. Fowler. AT1 and AT2 angiotensin receptor gene expression in human heart failure. Circulation 95: 1201-1206, 1997.
16. Husain, A. The chymase-angiotensin system in humans. J. Hypertens. 11: 1155-1159, 1993.
17. Kojima, M., I. Shiojima, T. Yamazaki, I. Komuro, Z. Yunzeng, W. Ying, T. Mizuno, K. Ueki, K. Tobe, T. Kadowaki, R. Nagai, and Y. Yazaki. Angiotensin II receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch-mediated cardiomyocyte hypertrophy in vivo. Circulation 89: 2204-2211, 1994.
18. Konstam, M. A., M. F. Rousseau, M. W. Kronenberg, J. E. Udelson, J. Melin, D. Stewart, N. Dolan, T. R. Edens, S. Ahn, D. Kinan, D. M. Howe, L. Kilcoyne, J. Metherall, C. Benedict, S. Yusuf, and H. Pouleur. Effects of the angiotensin converting enzyme inhibitor enalapril on long-term progression of left ventricular dysfunction in patients with heart failure. Circulation 86: 431-438, 1992.
19. Kurabayashi, M., and Y. Yazaki. Downregulation of angiotensin II receptor type I in heart failure. A process of adaptation or deterioration? Circulation 95: 1104-1107, 1997.
20. Lindpainter, K., and D. Ganten. The cardiac renin-angiotensin system. An appraisal of present experimental and clinical evidence. Circ. Res. 68: 905-921, 1991.
21. Liu, Y.-H., X.-P. Yang, V. G. Sharov, O. Nass, H. N. Sabbah, E. Peterson, and O. A. Carretero. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. J. Clin. Invest. 99: 1926-1935, 1997.
22. McDonald, K. M., M. Garr, P. F. Carlyle, G. S. Francis, K. Hauer, D. W. Hunter, T. Parish, A. Stillman, and J. N. Cohn. Relative effects of α1-adrenoceptor blockade, converting enzyme inhibitor therapy, and angiotensin II subtype 1 receptor blockade on ventricular remodeling. Circulation 90: 3034-3046, 1994.
23. McDonald, K. M., J. Mock, A. D'Aloia, T. Parrish, K. Hauer, G. Francis, A. Stillman, and J. N. Cohn. Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis. Circulation 91: 2043-2048, 1995.
24. Meggs, L. G., J. Coupet, H. Huang, W. Cheng, P. Li, J. M. Capasso, C. J. Homey, and P. Anversa. Regulation of angiotensin II receptors on ventricular myocytes after myocardial infarction in rats. Circ. Res. 72: 1149-1162, 1993.
25. Meiracker, A. H., P. J. J. Admiraal, J. A. Janssen, J. M. Kroodsma, W. A. de Ronde, F. Boomsma, J. Sissmann, P. J. Blankestijn, P. G. Mulder, and A. J. Man In't Veld. Hemodynamic and biochemical effects of the ATI receptor antagonist irbesartan in hypertension. Hypertension 25: 22-29, 1995.
26. Menard, J., D. J. Campbell, M. Azizi, and M. F. Gonzales. Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats. Circulation 96: 3072-3078, 1997.
27. Milavetz, J. J., T. E. Raya, C. S. Johnson, E. Morkin, and S. Goldman. Survival after myocardial infarction in rats: captopril versus losartan. J. Am. Coll. Cardiol. 27: 714-719, 1996.
28. Obayashi, M., M. Yano, M. Kohno, S. Kobayashi, T. Tanigawa, K. Hironaka, T. Ryouke, and M. Matsuzaki. Dosedependent effect of ANG II-receptor antagonist on myocyte remodeling in rat cardiac hypertrophy. Am. J. Physiol. 273 (Heart Circ. Physiol. 42): H1824-H1831, 1997.
29. Pitt, B., R. Segal, F. A. Martinez, G. Meurers, A. J. Cowley, I. Thomas, P. C. Deedwania, D. E. Ney, D. B. Snavely, and P. I. Chang. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349: 747-752, 1997.
30. Regitz-Zagrosek, V., N. Freidel, A. Heymann, P. Bauer, M. Neub, A. Rolfs, C. Steffen, A. Hildebrandt, R. Hetzer, and E. Fleck. Regulation, chamber localization, and subtype distribution of angiotensin II receptors in human hearts. Circulation 91: 1461-1471, 1995.
31. Sabbah, H. N., V. G. Sharov, M. Lesch, and S. Goldstein. Progression of heart failure: a role for interstitial fibrosis. Mol. Cell. Biochem. 147: 29-34, 1995.
32. Sabbah, H. N., H. Shimoyama, T. Kono, R. C. Gupta, V. G. Sharov, G. Scicli, T. B. Levine, and S. Goldstein. Effects of long-term monotherapy with enalapril, metoprolol, and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction. Circulation 89: 2852-2859, 1994.
33. Sabbah, H. N., P. D. Stein, T. Kono, M. Gheorghiade, T. B. Levine, S. Jafri, E. T. Hawkins, and S. Goldstein. A canine model of chronic heart failure produced by multiple sequential coronary microembolizations. Am. J. Physiol. 260 (Heart Circ. Physiol. 29): H1379-H1384, 1991.
34. Sechi L. A., C. A. Griggin, E. F. Grady, J. E. Kalinyak, and M. Schambelan. Characterization of angiotensin II receptor sub-types in rat heart. Circ. Res. 71: 1482-1489, 1992.
35. Sharov, V. G., H. N. Sabbah, H. Shimoyama, A. V. Goussev, M. Lesch, and S. Goldstein. Evidence of cardiocyte apoptosis in myocardium of dogs with chronic heart failure. Am. J. Pathol. 148: 141-149, 1996.
36. Smith J. F. M., and M. J. A. P. Daemen. Insights from animal models of myocardial infarction: do ACE inhibitors limit the structural response? Br. Heart J. 72: S61-S64, 1994.
37. Spinale, F. G., M. de Gasparo, S. Whitebread, L. Hebbar, M. J. Clai, M. Melton, S. Krombach, R. Mukherjee, J. P. Iannini, and O. Seung-Jun. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure. I. Effects on left ventricular performance and neurohormonal system. Circulation 96: 2385-2396, 1997.
38. Spinale, F. G., R. Mukherjee, J. P. Iannini, S. Whitebread, L. Hebbar, M. J. Clair, M. Melton, M. H. Cox, P. B. Thomas, and M. de Gasparo. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure. II. Effects on myocyte contractile processes. Circulation 96: 2397-2406, 1997.
39. Tanaka, M., J. Ohnishi, Y. Ozawa, M. Sugimoto, S. Usuki, M. Naruse, K. Murakami, and H. Miyazaki. Characterization of angiotensin II receptor type 2 during differentiation and apoptosis of rat ovarian cultured granulosa cells. Biochem. Biophys. Res. Commun. 207: 593-598, 1995.
40. Timmermans, P. B. M. W., and R. D. Smith. Angiotensin II receptor subtypes: selective antagonists and functional correlates. Eur. Heart J. 15: 79-87, 1994.
41. Timmermans, P. B. M. W., P. C. Wong, A. T. Chiu, W. F. Herblin, P. Benfield, D. J. Carini, R. J. Lee, R. R. Wexler, J. A. M. Saye, and R. D. Smith. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol. Rev. 45: 205-251, 1993.
42. Whitebread, S., B. Mele, B. Kamber, and M. de Casparo. Preliminary biochemical characterization of two angiotensin II receptor subtypes. Biochem. Biophys. Res. Commun. 163: 284-291, 1989.
43. Yamada T., M. Horiuchi, and V. J. Dzau. Angiotensin II type 2 receptor mediates programmed cell death. Proc. Natl. Acad. Sci. USA 93: 156-160, 1996.